Anti-inflammatory Drugs (Quelle) Flashcards
inflammatory cytokines released by phagocytes that provoke a fever response from the hypothalamus and activation of complement in the liver
IL-1 (hypothalamus)
IL-6 and TNF-alpha (liver)
cytokine that activates bystander neutrophils, causing them to produce proteases that increase tissue destruction
IL-6
activity of this type of cell and its secretion of cytokines is stimulated by T-cell cytokine release, antibody/antigen complexes and PAMPs
macrophage
in addition to secreting cytokines, fibroblasts, endothelial, and epithelial cells secrete these chemical attractants to draw nearby responsive cells to the site of infection
chemokines
drugs which commonly target the cytokines that promote/amplify inflammatory activity
disease-modifying antirheumatic drugs (DMARDs)
Which of the following is NOT a characteristic associated with Infliximab?
A. Increases risk of respiratory and urinary infections
B. Must be administered parenterally
C. Is a humanized antibody that prevents TNF-alpha association with its receptor
D. Works best when administered on its own
E. Is used to treat RA and Chron’s disease
D.
On the contrary, infliximab is usually administered with methotrexate for the treatment of RA and with azathioprine in the treatment of Chron’s disease.
TNF-alpha antibody whose mechanism, usage and complications are similar to infliximab
adalimumab
TNF-alpha antibody that has long lasting effects, because it is a fusion protein, containing the ligand binding domain of the TNF-alpha receptor and the Fc domain of human IgG
etanercept
competitive IL-1 receptor antagonist with a short half life that must be administered via daily injection; useful in treating RA but increases risk of infection
anakinra
more than 60 known cytokines utilize this receptor signaling complex, which plays an important role in stimulating the adaptive immune response
JAK/STAT signaling complex
the two cytokines discussed that do NOT use the JAK/STAT signaling pathway
IL-1 and TNF-alpha
Which of these is NOT a characteristic of the JAK kinase inhibitor Tofacitinib?
A. It’s the second line therapy for those failing on methotrexate therapy
B. It inhibits all cytokines required for adaptive immune response
C. It’s only approved use is currently Chron’s disease, though indication is likely to expand
D. adverse effects include neutropenia, myelosuppression and increased risk herpes zoster
E. long-term safety is currently unknown
C.
Currently, the only approved use for tofacitinib is rheumatoid arthritis (RA) though there are other JAK kinase inhibitors in development and clinical trials, and their use is likely to expand beyond this.
lipid mediators of inflammation are produced and released from leukocytes in response to signals that activate what enzyme?
phospholipase A2 (PLA2)
what important physiologic role does activated PLA2 have?
it hydrolyzes phosphotidylcholine in the plasma membrane to free arachidonic acid (AA), and then AA is used for the synthesis of lipid mediators
name the 2 types of lipid mediators discussed in class, the enzymes that produce them, and the drugs that inhibit their production
prostaglandins - produced by cyclooxygenase - inhibited by NSAIDs
leukotrienes - produced by lipoxygenase - inhibited by zileuton
STORED mediators are released in response to signals that activate this enzyme
phospholipase C (PLC)
what important physiologic role does activated PLC have?
PLC activates signaling pathways that increase intracellular Ca2+ mobilization and promote degranulation of lipid storing vesicles
what 2 drugs (mechanism unknown) inhibit the PLC pathway and degranulation of lipid storing vesicles?
cromolyn and nedocromil
glucocorticoids increase the expression of this protein, which inhibits phospholipase A2 (PLA2)
annexin (lipocortin)
Which of these is NOT a mechanism by which glucocorticoids exert their effect?
A. reduced production of inflammatory cytokines
B. reduced production of B cell antibodies
C. decreased synthesis of lipid mediators
D. increased expression of annexin
E. direct blocking of cyclooxygenase
E.
glucocorticoids do not act directly on cyclooxygenase, as NSAIDs do, but act further up the chain to decrease the synthesis of arachidonic acid, which cyclooxygenase uses as a substrate for prostaglandin synthesis. They also work at a transcriptional level to decrease the synthesis of enzymes needed for prostaglandin production (e.g., COX, PLA2 and NO synthase).
histamine intolerance results from deficiency or reduced activity of what enzyme?
diamine oxidase
what is the enzyme that converts histidine to histamine?
histidine decarboxylase
what are the main sites of production of histamine, and what function does it serve in these two locations?
- tissues. particularly those with a higher chance of injury (e.g., mouth, nose, hands/feet, blood vessels at bifurcations, GI mucosa). histamine is released from mast cells in response to IgE, and increases the permeability of the capillaries to allow leukocytes better access to pathogens in infected tissues.
- central nervous system. acts as neurotransmitter, released from neurons in the hypothalamus. main purpose is to promote wakefulness.
Which of these histamine receptors is NOT matched with its corresponding site of action?
A. H1 - Smooth/cardiac muscle
B. H2 - Gastric parietal cells
C. H3 - Mast cells
D. H4 - CD4 T cells
C.
H3 receptors are found on pre-synaptic terminals in the CNS.
Additionally:
H1 - found on smooth/cardiac muscle, endothelium, sensory nerve terminals, post-synaptic CNS
H2 - found on gastric parietal cells, mast cells, cardiac muscle, post-synaptic CNS
H4 - found on CD4 T cells, eosinophils and neutrophils